# A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

> **NCT06602024** · PHASE3 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 40817 (actual)

## Conditions studied

- Seasonal Influenza

## Interventions

- **BIOLOGICAL:** mRNA-1010
- **BIOLOGICAL:** Fluarix®
- **BIOLOGICAL:** Influsplit® Tetra
- **BIOLOGICAL:** Fluarix Tetra
- **BIOLOGICAL:** Alpharix® Tetra

## Key facts

- **NCT ID:** NCT06602024
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-16
- **Primary completion:** 2025-08-21
- **Final completion:** 2025-08-21
- **Target enrollment:** 40817 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06602024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06602024, "A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06602024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*